Abstract
Insulin secretion and insulin sensitivity are impaired in Type 2 diabetes. Metformin improves insulin sensitivity by inhibiting hepatic glucose release. It is the preferred drug for first-line treatment in Type 2 diabetes. Sitagliptin, the first marketed dipeptidyl peptidase-IV inhibitor, improves insulin and glucagon secretions of the pancreatic β- and α-cells, respectively, in a strictly glucose-dependent manner by raising endogenous active glucagon-like peptide-1 concentrations. The combination of metformin and sitagliptin thus offers a beneficial and complementary addition of important drug actions on insulin resistance and insulin secretion. Metformin and sitagliptin are also available as a fixed-dose combination. This article reviews the published clinical studies on both substances and their combination, and evaluates the potential benefit of the metformin plus sitagliptin combination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
